CD274 and head and neck squamous cell carcinoma: Treatment with immune checkpoint inhibitors (iCPi) targeting the programmed death receptor 1 (PD-1), like nivolumab and pembrolizumab and its ligand PD-L1 (atezolizumab), had significant clinical effects in a subset of HNSCC patients.